Высоцкая И.В. Эндокринно-чувствительные опухоли репродуктивной системы: руководство для врачей. М.: Спец. изд-во мед. кн. (СИМК). 2014. 126 р.

2. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена филиал ФГБУ "НМИРЦ" Минздрава России; 2018. 250 р.

3. Amin M.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging//CA. Cancer J. Clin. 2017. Vol. 67, N 2. P. 93 - 99.

4. Mayer I et al. (PDF) Breast cancer version 3.2014|Ingrid Mayer - Academia.edu [Electronic resource]. URL: https://www.academia.edu/21178012/Breast_cancer_version_3.2014 (accessed: 14.12.2019).

5. Hassan L.M. et al. Evaluation of effect of self-examination and physical examination on breast cancer//Breast Edinb. Scotl. 2015. Vol. 24, N 4. P. 487 - 490.

6. Liu X, Meng QH, Ye Y. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. - PubMed - NCBI. 2015. Vol. 36, N 2. P. 243 - 248.

7. Elyasinia F, Keramati MR, Ahmadi F. Neutrophil-Lymphocyte Ratio in Different Stages of Breast Cancer. -//Acta Med Iran. 2017. Vol. 55, N 4. P. 228 - 232.

8. Vernieri C, Mennitto A, Prisciandaro M, Prisciandaro M. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple n...//Sci Rep. 2018. Vol. 8, N 1. P. 8703.

9. S. et al. Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substance//Drug Des. Devel. Ther. 2015. Vol. 9. P. 1481 - 1490.

10. Tas F., Kilic L., Duranyildiz D. Coagulation tests show significant differences in patients with breast cancer//Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 2014. Vol. 35, N 6. P. 5985 - 5992.

11. Pedersen L.M., P.G. Increased urinary albumin excretion rate in breast cancer patients//Acta Oncol. Stockh. Swed. 2000. Vol. 39, N 2. P. 145 - 149.

12. Hammond M.E.H. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)//Arch. Pathol. Lab. Med. 2010. Vol. 134, N 7. P. e48 - 72.

13. Wolff A.C. et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary//J. Oncol. Pract. 2018. Vol. 14, N 7. P. 437 - 441.

14. Zhang X.-H., Xiao C. Diagnostic Value of Nineteen Different Imaging Methods for Patients with Breast Cancer: a Network Meta-Analysis//Cell. Physiol. Biochem. 2018. Vol. 46, N 5. P. 2041 - 2055.

15. Myers R.E. et al. Baseline staging tests in primary breast cancer: a practice guideline//CMAJ Can. Med. Assoc. J. 2001. Vol. 164, N 10. P. 1439 - 1444.

16. Crump M. et al. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1996. Vol. 14, N 1. P. 66 - 69.

17. Rayter Z. et al. Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls//Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 1994. Vol. 20, N 2. P. 134 - 140.

18. Kosmin M. et al. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer//Eur. J. Cancer Oxf. Engl. 1990. 2017. Vol. 77. P. 109 - 116.

19. Wang M. et al. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta-analysis//Breast Edinb. Scotl. 2017. Vol. 31. P. 157 - 166.

20. Petrelli F. et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients//Breast Cancer Res. Treat. 2015. Vol. 153, N 3. P. 477 - 491.

21. P. et al. Prognostic value of HER2-positive circulating tumor cells in breast cancer patients//Cancer Res. 2006. Vol. 66, N 8 Supplement. P. 458 - 459.

22. Noordhoek I. et al. Higher ER load is not associated with better outcome in stage 1 - 3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer//Breast Cancer Res. Treat. 2019. Vol. 176, N 1. P. 27 - 36.

23. Barco I. et al. Role of axillary ultrasound, magnetic resonance imaging, and ultrasound-guided fine-needle aspiration biopsy in the preoperative triage of breast cancer patients//Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex. 2017. Vol. 19, N 6. P. 704 - 710.

24. Yu Y.-H. et al. Axillary fine needle aspiration cytology is a sensitive and highly specific technique for the detection of axillary lymph node metastasis: a meta-analysis and systematic review//Cytopathology. 2016. Vol. 27, N 1. P. 59 - 69.

25. Wang X.-W. et al. Diagnostic accuracy of ultrasonograph guided fine-needle aspiration cytologic in staging of axillary lymph node metastasis in breast cancer patients: a meta-analysis//Asian Pac. J. Cancer Prev. APJCP. 2012. Vol. 13, N 11. P. 5517 - 5523.

26. Liikanen J. et al. Breast cancer prognosis and isolated tumor cell findings in axillary lymph nodes after core needle biopsy and fine needle aspiration cytology: Biopsy method and breast cancer outcome//Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2016. Vol. 42, N 1. P. 64 - 70.

27. Scully O.J. et al. Breast cancer metastasis//Cancer Genomics Proteomics. 2012. Vol. 9, N 5. P. 311 - 320.

28. Fares J. et al. Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations//Clin. Breast Cancer. 2019. Vol. 19, N 6. P. 383 - 391.

29. Arab C. et al. Cardiac autonomic modulation impairments in advanced breast cancer patients//Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2018. Vol. 107, N 10. P. 924 - 936.

30. M. et al. Pregnancy associated breast cancer//Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2009. Vol. 35, N 2. P. 215 - 218.

31. Peccatori F.A. et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2013. Vol. 24 Suppl 6. P. vi160 - 170.

32. Stensheim H. et al. Pregnancy after adolescent and adult cancer: a population-based matched cohort study//Int. J. Cancer. 2011. Vol. 129, N 5. P. 1225 - 1236.

33. Shachar S.S. et al. Multidisciplinary Management of Breast Cancer During Pregnancy//The Oncologist. 2017. Vol. 22, N 3. P. 324 - 334.

34. Keleher A.J. et al. Multidisciplinary management of breast cancer concurrent with pregnancy//J. Am. Coll. Surg. 2002. Vol. 194, N 1. P. 54 - 64.

35. NCCN Clinical Practice Guidelines in Oncology for Older Adult Oncology. [Electronic resource]//National Comprehensive Cancer Network. 2019. URL: https://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=1578 (accessed: 18.12.2019).

36. Gradishar W.J. et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology//J. Natl. Compr. Cancer Netw. JNCCN. 2016. Vol. 14, N 3. P. 324 - 354.

37. Ferreira Poloni P. et al. Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study//Climacteric J. Int. Menopause Soc. 2017. Vol. 20, N 5. P. 491 - 497.

38. Coelho RC et al. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy? The Breast 31 (2017) 192 - 196.

39. Wang G.-L. et al. Radioactive seed localization and wire guided localization in breast cancer: A systematic review and meta-analysis//J. BUON Off. J. Balk. Union Oncol. 2019. Vol. 24, N 1. P. 48 - 60.

40. Serban M. et al. Computed tomography-based virtual simulation versus ultrasound-based clinical setup in electron breast boost radiotherapy: Methodology for CT-based electron virtual simulation//Phys. Medica PM Int. J. Devoted Appl. Phys. Med. Biol. Off. J. Ital. Assoc. Biomed. Phys. AIFB. 2019. Vol. 67. P. 100 - 106.

41. Marks, L.B. Use of normal tissue complication probability models in the clinic. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC)/L.B. Marks//Int J Radiat Oncol Biol Phys 2010; 76(3). P. 120 - 145.

42. ICRU Report 50, Report 62. Journal of the ICRU Issueded: 1 November 1999; ICRU Report 83. Journal of the ICRU 2010; 10(1).

43. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. 2020.

44. Cardoso F, Kyriakides S, Ohno S. ESMO Clinical Practice Guidelines|Early Breast Cancer|ESMO. 2019. N 1194 - 1220. P. 30.

45. Dunne C. et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, N 10. P. 1615 - 1620.

46. Rizki, H., Nkonde, C., Ching, R.C., Kumiponjera, D., & Malata, C.M. (2013). Plastic surgical management of the contralateral breast in post-mastectomy breast reconstruction. International Journal of Surgery, 11(9), 767 - 772.

47. Kirby A.N. et al. Tumour bed delineation for partial breast/breast boost radiotherapy: what is the optimal number of implanted markers?//Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2013. Vol. 106, N 2. P. 231 - 235.

48. Naoura I. et al. Factors influencing the decision to offer immediate breast reconstruction after mastectomy for ductal carcinoma in situ (DCIS): The Institut Gustave Roussy Breast Cancer Study Group experience//The Breast. - 2013. - T. 22. - N 5. - C. 673 - 675.

49. Thiessen F.E.F., Tjalma W.A.A., Tondu T. Breast reconstruction after breast conservation therapy for breast cancer//European Journal of Obstetrics & Gynecology and Reproductive Biology. - 2018. - T. 230. - C. 233 - 238.

50. Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30): 7703 - 20. Epub 2005 Sep 12.

51. Iida S. et al. Evaluation of sentinel lymph node biopsy in clinically node-negative breast cancer//J. Nippon Med. Sch. Nippon Ika Daigaku Zasshi. 2011. Vol. 78, N 2. P. 96 - 100.

52. Clements K. et al. Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ//Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2015. Vol. 41, N 10. P. 1406 - 1410.

53. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006 Jul 20; 24(21): 3381 - 7. Epub 2006 Jun 26.

54. Shurell E. et al. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ//Cancer. 2018. Vol. 124, N 1. P. 46 - 54.

55. Staley H., McCallum I., Bruce J. Postoperative tamoxifen for ductal carcinoma in situ//Cochrane Database Syst. Rev. 2012. Vol. 10. P. CD007847.

56. Margolese R.G. et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial//Lancet Lond. Engl. 2016. Vol. 387, N 10021. P. 849 - 856.

57. Glechner A. et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis//Eur. J. Cancer Oxf. Engl. 1990. 2013. Vol. 49, N 4. P. 812 - 825.

58. S. et al. Breast conserving therapy versus mastectomy for stage I - II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial//Lancet Oncol. 2012. Vol. 13, N 4. P. 412 - 419.

59. Moran M.S. et al. SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer//Int. J. Radiat. Oncol. Biol. Phys. 2014. Vol. 88, N 3. P. 553 - 564.

60. Povoski S.P. et al. Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer//BMC cancer. - 2009. - T. 9. - N 1. - C. 254.

61. Giuliano A.E. et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial//JAMA. 2017. Vol. 318, N 10. P. 918 - 926.

62. Libson S. et al. Post Mastectomy Radiation for Stage II Breast Cancer Patients with T1/T2 Lesions//Eur. J. Breast Health. 2019. Vol. 15, N 2. P. 71 - 75.

63. Fisher B. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer//N. Engl. J. Med. 2002. Vol. 347, N 16. P. 1233 - 1241.

64. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials//Lancet Lond. Engl. 2011. Vol. 378, N 9804. P. 1707 - 1716.

65. Bartelink H. et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial//Lancet Oncol. 2015. Vol. 16, N 1. P. 47 - 56.

66. Haviland J.S, Owen J.L., Dewar J. The UK Standartisation of Breast Radiotherapy hypofractionination for treatment (START) of early breast-cancer: 10-year follow-up results of two randomized controlled trials.//Lancet Oncol. 2013. Vol. 14. P. 1086 - 1094.

67. Collaborative G., Darby S., McGale P. Early Breast Cancer Trialists. Effect of radiotherapy after breast -conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials.//Lancet. 2011. Vol. 378, N 1707. P. 1716 - 1716.

68. Budach W. et al. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials - an update//Radiat. Oncol. Lond. Engl. 2015. Vol. 10. P. 258.

69. Yun-Fen Li, Li Chang, Wen-Hui Li et al. Radiotherapy Concurrent Versus Sequential With Endocrine Therapy in Breast Cancer: A Meta-Analysis. Breast. 2016 Jun; 27: 93 - 8.

70. Стенина М.Б., Жукова Л.Г., Королева И.А. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы.//Злокачественные опухоли. 2018. N 8. Р. 113 - 144.

71. Sparano J.A. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer//New England Journal of Medicine. - 2008. - T. 358. - N 16. - C. 1663 - 1671.

72. Citron, M.L., Berry, D.A., Cirrincione et al. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. Journal of Clinical Oncology 2005; 23(16_suppl), 620 - 620.

73. Goldhirsch A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2013. Vol. 24, N 9. P. 2206 - 2223.

74. Tashima R. et al. P260 Evaluation of PgR expression as a prognostic factor in luminal HER2-negative breast cancer//The Breast. 2015. Vol. 24. P. S116.

75. Coates A.S. et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015. Vol. 26, N 8. P. 1533 - 1546.

76. Curigliano G. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017. Vol. 28, N 8. P. 1700 - 1712.

77. Burstein H.J. et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019. Vol. 30, N 10. P. 1541 - 1557.

78. Goldhirsch A. et al. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG)//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 1998. Vol. 9, N 5. P. 489 - 493.

79. Jones S. et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, N 8. P. 1177 - 1183.

80. Fisher B. et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1990. Vol. 8, N 9. P. 1483 - 1496.

81. Martin M. et al. Adjuvant docetaxel for node-positive breast cancer//N. Engl. J. Med. 2005. Vol. 352, N 22. P. 2302 - 2313.

82. H. et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2006. Vol. 24, N 36. P. 5664 - 5671.

83. M. et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer//J. Natl. Cancer Inst. 2008. Vol. 100, N 11. P. 805 - 814.

84. Romond E.H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer//N. Engl. J. Med. 2005. Vol. 353, N 16. P. 1673 - 1684.

85. Jones S.E. et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study//Lancet Oncol. 2013. Vol. 14, N 11. P. 1121 - 1128.

86. Tolaney S.M. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer//N. Engl. J. Med. 2015. Vol. 372, N 2. P. 134 - 141.

87. Gianni L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial//Lancet Oncol. 2012. Vol. 13, N 1. P. 25 - 32.

88. Jones S.E. et al. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer//J. Clin. Oncol. 2006. Vol. 24, N 34. P. 5381 - 5387.

89. van Rossum A.G.J. et al. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)//Eur. J. Cancer Oxf. Engl. 1990. 2018. Vol. 102. P. 40 - 48.

90. Watanabe T. et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study//Cancer. 2017. Vol. 123, N 5. P. 759 - 768.

91. Ferreira Filho A.F. et al. The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2002. Vol. 13, N 3. P. 416 - 421.

92. Masuda N. et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy//N. Engl. J. Med. 2017. Vol. 376, N 22. P. 2147 - 2159.

93. von Minckwitz G. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer//N. Engl. J. Med. 2019. Vol. 380, N 7. P. 617 - 628.

94. Regan M.M. Predicting Benefit of Endocrine Therapy for Early Breast Cancer//Breast Edinb. Scotl. 2015. Vol. 24, N 0 2. P. S129 - S131.

95. Tevaarwerk A.J. et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014. Vol. 32, N 35. P. 3948 - 3958.

96. Bernhard J. et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).//J. Clin. Oncol. 2014. Vol. 32. P. 557 - 557.

97. Bernhard J. et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).//J. Clin. Oncol. 2014. Vol. 32, N 15_suppl. P. 557 - 557.

98. Viale G. et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial//Ann. Oncol. 2011. Vol. 22, N 10. P. 2201 - 2207.

99. Ribi K. et al. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial//J. Clin. Oncol. 2016. Vol. 34, N 14. P. 1601 - 1610.

100. Boccardo F. et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients//Cancer Chemother. Pharmacol. 1999. Vol. 43, N 6. P. 461 - 466.

101. Karakatsanis A. et al. Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer//Br. J. Surg. 2018. Vol. 105, N 5. P. 469 - 481.

102. Criscitiello C. et al. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis//Eur. J. Cancer Oxf. Engl. 1990. 2018. Vol. 97. P. 1 - 6.

103. Bines J. et al. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2014. Vol. 25, N 6. P. 1079 - 1085.

104. Fisher B. et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1997. Vol. 15, N 7. P. 2483 - 2493.

105. Bonadonna G. et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1998. Vol. 16, N 1. P. 93 - 100.

106. Cameron D.A. et al. Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy//Br. J. Cancer. 1997. Vol. 76, N 8. P. 1099 - 1105.

107. Liedtke C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008. Vol. 26, N 8. P. 1275 - 1281.

108. Cortazar P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis//Lancet Lond. Engl. 2014. Vol. 384, N 9938. P. 164 - 172.

109. Allevi G. et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer//Br. J. Cancer. 2013. Vol. 108, N 8. P. 1587 - 1592.

110. Dowsett M. et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer//J. Natl. Cancer Inst. 2007. Vol. 99, N 2. P. 167 - 170.

111. Dowsett M. PG 8.02 Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints//The Breast. 2015. Vol. 24. P. S14.

112. Bossuyt V. et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015. Vol. 26, N 7. P. 1280 - 1291.

113. S. et al. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy//Breast Cancer Res. Treat. 2013. Vol. 139, N 3. P. 759 - 767.

114. Vriens B.E.P.J. et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer//Breast Cancer Res. Treat. 2017. Vol. 165, N 3. P. 593 - 600.

115. Sugitani I. et al. Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety//Int. J. Clin. Oncol. 2017. Vol. 22, N 5. P. 880 - 886.

116. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials//Lancet Lond. Engl. 2019. Vol. 393, N 10179. P. 1440 - 1452.

117. Buzdar A.U. et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial//Lancet Oncol. 2013. Vol. 14, N 13. P. 1317 - 1325.

118. Llombart A. et al. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial//Clin. Breast Cancer. 2012. Vol. 12, N 1. P. 40 - 48.

119. Shen J. et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy//Ann. Surg. Oncol. 2004. Vol. 11, N 9. P. 854 - 860.

120. Cataliotti L. et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial//Cancer. 2006. Vol. 106, N 10. P. 2095 - 2103.

121. Debiasi M. et al. Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis//Front. Oncol. 2018. Vol. 8. P. 156.

122. Loughney L. et al. Exercise intervention in people with cancer undergoing neoadjuvant cancer treatment and surgery: A systematic review//Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2016. Vol. 42, N 1. P. 28 - 38.

123. Newman L.A. Management of patients with locally advanced breast cancer//Curr. Oncol. Rep. 2004. Vol. 6, N 1. P. 53.

124. Sun Y. et al. Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis//Medicine (Baltimore). 2017. Vol. 96, N 43. P. e8367.

125. Liu J. et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II - III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB//Oncotarget. 2016. Vol. 7, N 17. P. 24848 - 24859.

126. Valagussa P. et al. T3b - T4 breast cancer: factors affecting results in combined modality treatments//Clin. Exp. Metastasis. 1983. Vol. 1, N 2. P. 191 - 202.

127. Trovo M. et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial//Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2018. Vol. 126, N 1. P. 177 - 180.

128. Higgins M.J., Wolff A.C. Therapeutic options in the management of metastatic breast cancer//Oncol. Williston Park N. 2008. Vol. 22, N 6. P. 614 - 623; discussion 623, 627 - 629.

129. Kuss J.T. et al. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials//Breast Cancer Res. Treat. 1997. Vol. 42, N 3. P. 265 - 274.

130. Rugo H.S. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline//J. Clin. Oncol. 2016. Vol. 34, N 25. P. 3069 - 3103.

131. Klijn J.G. et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001. Vol. 19, N 2. P. 343 - 353.

132. Cardoso F. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer //Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, N 8. P. 1634 - 1657.

133. Howell A. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2004. Vol. 22, N 9. P. 1605 - 1613.

134. Di Leo A. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010. Vol. 28, N 30. P. 4594 - 4600.

135. B. et al. Anastrozole ("Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - A sub-study of the TARGET (Tamoxifen or "Arimidex" Randomized Group Efficacy and Tolerability) trial//Breast Cancer Res. Treat. 2004. Vol. 85. P. 247 - 254.

136. Mouridsen H. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001. Vol. 19, N 10. P. 2596 - 2606.

137. Muss H.B. et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1994. Vol. 12, N 8. P. 1630 - 1638.

138. Baselga J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer//N. Engl. J. Med. 2012. Vol. 366, N 6. P. 520 - 529.

139. Chan S. et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1999. Vol. 17, N 8. P. 2341 - 2354.

140. Bastholt L. et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1996. Vol. 14, N 4. P. 1146 - 1155.

141. O'Brien M.E.R. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX^TM/Doxil^(R)) versus conventional doxorubicin for first-line treatment of metastatic breast cancer//Ann. Oncol. 2004. Vol. 15, N 3. P. 440 - 449.

142. Jones S.E. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005. Vol. 23, N 24. P. 5542 - 5551.

143. Seidman A.D. et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008. Vol. 26, N 10. P. 1642 - 1649.

144. Perez E.A. et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001. Vol. 19, N 22. P. 4216 - 4223.

145. Burris H.A. Single-agent docetaxel (Taxotere) in randomized phase III trials//Semin. Oncol. 1999. Vol. 26, N 3 Suppl 9. P. 1 - 6.

146. Burstein H.J. et al. Docetaxel administered on a weekly basis for metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2000. Vol. 18, N 6. P. 1212 - 1219.

147. Gradishar W.J. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005. Vol. 23, N 31. P. 7794 - 7803.

148. Gradishar W.J. et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, N 22. P. 3611 - 3619.

149. Zelek L. et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma//Cancer. 2001. Vol. 92, N 9. P. 2267 - 2272.

150. H. et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, N 23. P. 3415 - 3420.

151. Rivera E., Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone//Breast Cancer Res. BCR. 2010. Vol. 12, N Suppl 2. P. S2.

152. Denduluri N. et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, N 23. P. 3421 - 3427.

153. Perez E.A. et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, N 23. P. 3407 - 3414.

154. Thomas E. et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, N 23. P. 3399 - 3406.

155. Cortes J. et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010. Vol. 28, N 25. P. 3922 - 3928.

156. Vahdat L.T. et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, N 18. P. 2954 - 2961.

157. Cortes J. et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study//Lancet Lond. Engl. 2011. Vol. 377, N 9769. P. 914 - 923.

158. Blum J.L. et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1999. Vol. 17, N 2. P. 485 - 493.

159. O'Shaughnessy J. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2002. Vol. 20, N 12. P. 2812 - 2823.

160. Bajetta E. et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005. Vol. 23, N 10. P. 2155 - 2161.

161. Blackstein M. et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial//Oncology. 2002. Vol. 62, N 1. P. 2 - 8.

162. Rha S.Y. et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer//Breast Cancer Res. Treat. 2005. Vol. 90, N 3. P. 215 - 221.

163. Albain K.S. et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008. Vol. 26, N 24. P. 3950 - 3957.

164. Mauri D. et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis//Cancer Treat. Rev. 2010. Vol. 36, N 1. P. 69 - 74.

165. Sparano J.A. et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010. Vol. 28, N 20. P. 3256 - 3263.

166. Sirohi B. et al. Platinum-based chemotherapy in triple-negative breast cancer//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2008. Vol. 19, N 11. P. 1847 - 1852.

167. Wang Z. et al. Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial.//J. Clin. Oncol. 2010. Vol. 28, N 15_suppl. P. 1100 - 1100.

168. Chew H.K. et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, N 13. P. 2163 - 2169.

169. Staudacher L. et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2011. Vol. 22, N 4. P. 848 - 856.

170. Hirano A. et al. Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer//Anticancer Res. 2008. Vol. 28, N 6B. P. 4137 - 4142.

171. Horiguchi J. et al. Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer//Anticancer Res. 2009. Vol. 29, N 2. P. 517 - 524.

172. Seidman A.D. et al. Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification//J. Clin. Oncol. 2001. Vol. 19, N 10. P. 2587 - 2595.

173. Dieras V. et al. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC//Br. J. Cancer. 1996. Vol. 74, N 4. P. 650 - 656.

174. Ruiz M. et al. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer//Cancer Chemother. Pharmacol. 2008. Vol. 62, N 6. P. 1085 - 1090.

175. Miller K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer//N. Engl. J. Med. 2007. Vol. 357, N 26. P. 2666 - 2676.

176. Miles D.W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010. Vol. 28, N 20. P. 3239 - 3247.

177. Hurvitz S.A. et al. A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)//Clin. Breast Cancer. 2010. Vol. 10, N 4. P. 307 - 312.

178. Schmid P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer//N. Engl. J. Med. 2018. Vol. 379, N 22. P. 2108 - 2121.

179. Park J.H. et al. Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis//J. Breast Cancer. 2017. Vol. 20, N 4. P. 347 - 355.

180. Farhat F., Kattan J.G., Ghosn M. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer//Cancer Chemother. Pharmacol. 2016. Vol. 77, N 5. P. 1069 - 1077.

181. Yardley D.A. et al. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer//Clin. Breast Cancer. 2009. Vol. 9, N 3. P. 178 - 183.

182. Chitapanarux I. et al. Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy//Gan To Kagaku Ryoho. 2006. Vol. 33, N 6. P. 761 - 766.

183. Yardley D.A. et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial//Trials. 2015. Vol. 16, N 1. P. 575.

184. Sharma P. et al. Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.//J. Clin. Oncol. 2016. Vol. 34, N 15_suppl. P. 1015 - 1015.

185. Colleoni M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2002. Vol. 13, N 1. P. 73 - 80.

186. Giannone G et al. Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series. Breast. 2018 Apr; 38: 160 - 164.

187. Robson M.E. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019. Vol. 30, N 4. P. 558 - 566.

188. Yardley D.A. et al. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer//Clin. Breast Cancer. 2008. Vol. 8, N 5. P. 425 - 431.

189. Cazzaniga M.E., Dionisio M.R., Riva F. Metronomic chemotherapy for advanced breast cancer patients//Cancer Lett. 2017. Vol. 400. P. 252 - 258.

190. Swain S.M. et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer//N. Engl. J. Med. 2015. Vol. 372, N 8. P. 724 - 734.

191. Johnston S.R.D. et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE//J. Clin. Oncol. 2017. Vol. 36, N 8. P. 741 - 748.

192. Azambuja E. de et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response//Lancet Oncol. 2014. Vol. 15, N 10. P. 1137 - 1146.

193. Schwartzberg L.S. et al. Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer//The Oncologist. 2010. Vol. 15, N 2. P. 122 - 129.

194. Gradishar W.J. et al. Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.//J. Clin. Oncol. 2017. Vol. 35, N 15_suppl. P. 1004 - 1004.

195. Miles D. et al. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017. Vol. 28, N 11. P. 2761 - 2767.

196. Mast M.E. et al. Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients//Breast Cancer Res. Treat. 2014. Vol. 148, N 1. P. 33 - 39.

197. Stick L.B. et al. Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer//Int. J. Radiat. Oncol. Biol. Phys. 2017. Vol. 97, N 4. P. 754 - 761.

198. Meneses K.D. et al. Transition from treatment to survivorship: effects of a psychoeducational intervention on quality of life in breast cancer survivors//Oncol. Nurs. Forum. 2007. Vol. 34, N 5. P. 1007 - 1016.

199. Yates P. et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005. Vol. 23, N 25. P. 6027 - 6036.

200. Tatrow K., Montgomery G.H. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta-analysis//J. Behav. Med. 2006. Vol. 29, N 1. P. 17 - 27.

201. Golant M., Altman T., Martin C. Managing cancer side effects to improve quality of life: a cancer psychoeducation program//Cancer Nurs. 2003. Vol. 26, N 1. P. 37-44; quiz 45 - 46.

202. Chung C. et al. Systematic review of exercise effects on health outcomes in women with breast cancer//Asian Nurs. Res. 2013. Vol. 7, N 3. P. 149 - 159.

203. Ebid A.A., El-Sodany A.M. Long-term effect of pulsed high-intensity laser therapy in the treatment of post-mastectomy pain syndrome: a double blind, placebo-control, randomized study//Lasers Med. Sci. 2015. Vol. 30, N 6. P. 1747 - 1755.

204. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology//Lymphology. 2013. Vol. 46, N 1. P. 1 - 11.

205. Lacomba M.T. et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial//BMJ. 2010. Vol. 340.

206. Finnane A., Janda M., Hayes S.C. Review of the evidence of lymphedema treatment effect//Am. J. Phys. Med. Rehabil. 2015. Vol. 94, N 6. P. 483 - 498.

207. Szuba A., Achalu R., Rockson S.G. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression//Cancer. 2002. Vol. 95, N 11. P. 2260 - 2267.

208. Carati C.J. et al. Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial//Cancer. 2003. Vol. 98, N 6. P. 1114 - 1122.

209. Ahmed Omar M.T., Abd-El-Gayed Ebid A., El Morsy A.M. Treatment of post-mastectomy lymphedema with laser therapy: double blind placebo control randomized study//J. Surg. Res. 2011. Vol. 165, N 1. P. 82 - 90.

210. Piller N.B. et al. Placebo controlled trial of mild electrical stimulation//J. Lymphoedema. 2010. Vol. Lymphoedema 5.1 (2010): 15 - 2.

211. Грушина Т.И. Реабилитация пациенток после радикального лечения первичного рака молочной железы с помощью методов физической терапии//Физиотерапия Бальнеология Реабилитация. 2011. N 2. Р. 11 - 17.

212. Jahr S., Schoppe B., Reisshauer A. Effect of treatment with low-intensity and extremely low-frequency electrostatic fields (Deep Oscillation) on breast tissue and pain in patients with secondary breast lymphoedema//J. Rehabil. Med. 2008. Vol. 40, N 8. P. 645 - 650.

213. Shaw C., Mortimer P., Judd P.A. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema//Cancer. 2007. Vol. 109, N 10. P. 1949 - 1956.

214. Smith T.J. et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines//J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1999. Vol. 17, N 3. P. 1080 - 1082.

215. Espinosa-Bravo M. et al. Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods//Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2011. Vol. 37, N 12. P. 1038 - 1043.

216. Goodwin P.J. PG 6.03 Obesity and insulin resistance: clinical relevance and research priorities//The Breast. 2015. Vol. 24. P. S11 - S12.

217. von Minckwitz G, Raab G, Caputo A, M, Hilfrich J, Blohmer JU, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German breast group. J Clin Oncol. 2005. Vol. 23. P. 2676 - 85.

218. Buszek, Samantha M., et al. Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. International Journal of Radiation Oncology* Biology* Physics 2019 Nov 15; 105(4): 795 - 802.

219. Rowell N.P. Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review//Radiotherapy and Oncology. - 2009. - T. 91. - N 1. - C. 23 - 32.

220. Kosaka Y. et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy//Supportive Care in Cancer. - 2015. - T. 23. - N 4. - C. 1137 - 1143.

221. Gilbar P. et al. High incidence of febrile neutropenia following adjuvant breast chemotherapy with docetaxel, carboplatin and trastuzumab//Breast Cancer Management. - 2014. - T. 3. - N 4. - C. 327 - 333.

222. Итоговый отчет о результатах клинического исследования "Международное многоцентровое двойное слепое рандомизированное исследование эффективности и безопасности однократного применения препарата BCD-017 по сравнению с ежедневным введением филграстима с целью профилактики нейтропении у больных раком молочной железы, получающих миелосупрессивную химиотерапию, с двойным маскированием". 31.10.2014.

223. Huang T.W. et al. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system//International Journal of Surgery. - 2016. - T. 34. - C. 73 - 80.

224. Стенина М.Б., Жукова Л.Г., Королева И.А., Пароконная А.А., Семиглазова Т.Ю., Тюляндин С.А. и соавт. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2019 (том 9). С. 128 - 163.

225. Dang C. et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer//Journal of clinical oncology. - 2008. - T. 26. - N 8. - C. 1216 - 1222.

226. von Minckwitz G., M. Procter, E. de Azambuja. Adjuvant Pertuzumab and Trastuzumab in Early HER2 Positive Breast Cancer. N Engl J Med. - 2017. - Jul 13. - 377(2). - P. 122 131.

227. Sikov, W.M., D.A. Berry, C.M. Perou et al. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once per Week Paclitaxel Followed by Dose Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol. - 2014. - 33(1). - P. 13 21.

228. Spring, L., A. Niemierko, A.H. Comander et al. Tolerability and effectiveness of pertuzumab containing neoadjuvant (NA) regimens vs. AC TH for HER2 positive (+) localized breast cancer (BC) [ASCO abstr. 586]. J Clin Oncol. - 2016. - 34.

229. Schneeweiss A. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)//Annals of oncology. - 2013. - T. 24. - N 9. - C. 2278 - 2284.

230. Dhesy-Thind S, Fletcher GG, Blanchette PS et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 2017 35:18, 2062 - 2081.

231. Reinbolt RE, Mangini N, Hill JL, Levine LB, Dempsey JL, Singaravelu J, Koehler K, Talley A, Lustberg MB, Endocrine Therapy in Breast Cancer: the Neoadjuvant, Adjuvant, and Metastatic Approach, Seminars in Oncology Nursing (2015), doi: 10.1016/j.soncn.2015.02.002.

232. Cardoso F. et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)//Annals of Oncology. - 2017. - T. 28. - N 1. - C. 16 - 33.

233. Langley R.E. et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01//J Clin Oncol. - 2005. - T. 23. - N 33. - C. 8322 - 8330.

234. Bajetta E. et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005. 23: 2155 - 2161.

235. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35 - 40.

236. Blackwell KL et al. Randomized study of lapatinib alone or in combination with trastuzumab in woman with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28(7): 1124 - 30.

237. Abdulkarim B.S., Cuartero J., Hanson J. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant RT compared with breast conserving therapy J Clin Oncol 2011; 29: 2852 - 58.

238. Jagsi R., Raad R.A., Goldberg S. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy radiation Inst J Radiat Oncol Biol Phys 2005; 62: 1035 - 39.

239. Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB, Collette L, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Schinagl DA, CC, Bartelink H. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009 Oct 20; 27 (30): 4939 - 47. doi: 10.1200/JCO.2008.21.5764. Epub 2009 Aug 31.

240. Yun-Fen Li et al. Radiotherapy Concurrent Versus Sequential With Endocrine Therapy in Breast Cancer: A Meta-Analysis. Breast. 2016 Jun; 27: 93 - 8.

241. Mignot F et al. Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review. Radiother Oncol. 2017 Aug; 124(2): 190 - 199.

242. Veronesi U. Et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002 Oct 17; 347(16): 1227 - 32.

243. Fisher B. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17; 347(16): 1233 - 41.

244. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. 2018.

245. Hussain N. et al. Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. Int J Breast Cancer. 2018; 2018: 6106041.

246. Sousa C. et al. Neoadjuvant radiotherapy in the approach of locally advanced breast cancer//ESMO open. - 2020. - T. 4. - N Suppl 2. - C. e000640.